SEATTLE, Dec. 11, 2017 /PRNewswire/ — PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code…